Evidence map›Paper›PMID 27515250›Full record

ArticleHaematologica2016

A sequential approach with imatinib, chemotherapy and transplant for adult Ph+ acute lymphoblastic leukemia: final results of the GIMEMA LAL 0904 study.

Sabina Chiaretti, Antonella Vitale, Marco Vignetti, Alfonso Piciocchi, Paola Fazi, Loredana Elia, Brunangelo Falini, Francesca Ronco, Felicetto Ferrara, Paolo De Fabritiis and 9 more

3 registry-linked trialsOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Haematologica, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 55 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed, 4 pooled it
5.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00458848 phase2completednot on this map

Phase II Study of Adult Acute Lymphoblastic Leukaemia (ALL): Imatinib in Combination With Chemotherapy in Ph+ Patients, and Post-remissional Treatment Intensification in High-risk Ph- Patients, With Minimal Residual Disease Monitoring.

TypeinterventionalSponsorGruppo Italiano Malattie EMatologiche dell'AdultoRan2004 to 2014Enrolled470ConditionsLeukemiaArmsasparaginase, daunorubicin hydrochloride, etoposide, idarubicin, imatinib mesylate
NCT04554459 phase2terminatednot on this mapstarted 2021, after this paper: background citation

Ponatinib Plus Reduced-intensity Chemotherapy in the First-line Treatment of Adult Patients With Ph-positive Acute Lymphoblastic Leukemia

TypeinterventionalSponsorInstitute of Hematology and Blood Transfusion, Czech RepublicRan2021 to 2024Enrolled4ConditionsAcute Lymphoblastic Leukemia, Adult, Ph+ ALL, Newly DiagnosedArmsPonatinib 15 MG Oral Tablet
NCT06175702 not yet recruitingnot on this mapstarted 2023, after this paper: background citation

Treatment Protocol for Newky Diagnosed Adult Ph-Chromosome Positive (BCR::ABL1) Acute Lymphoblastic Leukemia (LALPh2022)

TypeobservationalSponsorPETHEMA FoundationRan2023 to 2030Enrolled150ConditionsLymphoblastic Leukemia, Philadelphia-Positive ALL, Adult ALLArmsVincristine, Dexamethasone, Imatinib, Cytarabine, Mercaptopurine
3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 4 syntheses or guidelines pooled it, 95 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Long-Term Results of the Dasatinib-Blinatumomab Protocol for Adult Philadelphia-Positive ALL.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024
    Article
  17. Article
  18. Minimal Residual Disease in the Management of B-Cell Acute Lymphoblastic Leukemia: A Systematic Review of Studies from Indian Settings.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2024
    Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 12 institutions in 1 country.

Sabina ChiarettiHematology, Department of Cellular Biotechnologies and Hematology, Policlinico Umberto 1, "Sapienza" University of Rome, Italy rfoa@bce.uniroma1.it chiaretti@bce.uniroma1.it.
Antonella VitaleHematology, Department of Cellular Biotechnologies and Hematology, Policlinico Umberto 1, "Sapienza" University of Rome, Italy.
Marco VignettiGIMEMA Data Center, Rome, Italy.
Alfonso PiciocchiGIMEMA Data Center, Rome, Italy.
Paola FaziGIMEMA Data Center, Rome, Italy.
Loredana EliaHematology, Department of Cellular Biotechnologies and Hematology, Policlinico Umberto 1, "Sapienza" University of Rome, Italy.
Brunangelo FaliniInstitute of Hematology, University of Perugia, Italy.
Francesca RoncoHematology Unit, Azienda Ospedaliera Bianchi Melacrino Morelli, Reggio Calabria, Italy.
Felicetto FerraraDivision of Hematology and Stem Cell Transplantation Unit, Cardarelli Hospital, Naples, Italy.
Paolo De FabritiisHematology Unit and Department of Pharmacy Services, Sant'Eugenio Hospital, Rome, Italy.
Mario LuppiHematology Division, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Modena, Italy.
Giorgio La NasaHematology Unit, Department of Medical Sciences, University of Cagliari, Italy.
Alessandra TedeschiDepartment of Oncology/Hematology, Niguarda Cancer Center, Niguarda Ca' Granda Hospital, Milano, Italy.
Catello CalifanoOncohematology Unit A. Tortora Hospital, Pagani, Salerno, Italy.
Renato FaninDivision of Hematology and Bone Marrow Transplantation, University Hospital, Udine, Italy.
Fausto DoreDepartment of Biomedical Sciences, University of Sassari, Italy.
Franco MandelliGIMEMA Data Center, Rome, Italy.
Giovanna MeloniHematology, Department of Cellular Biotechnologies and Hematology, Policlinico Umberto 1, "Sapienza" University of Rome, Italy.
Robin FoàHematology, Department of Cellular Biotechnologies and Hematology, Policlinico Umberto 1, "Sapienza" University of Rome, Italy rfoa@bce.uniroma1.it chiaretti@bce.uniroma1.it.
Fondazione Gimema Onlus · ITPoliclinico Umberto I · ITSapienza University of Rome · ITAzienda ospedaliera "Bianchi-Melacrino-Morelli" · ITAzienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda · ITFatebenefratelli Hospital · ITSt. Eugenio Hospital · ITUniversity of Cagliari · ITUniversity of Modena and Reggio Emilia · ITUniversity of Perugia · ITUniversity of Sassari · ITUniversity of Udine · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the GIMEMA LAL 0904 protocol, adult Philadelphia positive acute lymphoblastic leukemia patients were treated with chemotherapy for induction and consolidation, followed by maintenance with imatinib. The protocol was subsequently amended and imatinib was incorporated in the induction and post-remission phase together with chemotherapy. Due to the toxicity of this combined approach, the protocol was further amended to a sequential scheme based on imatinib plus steroids as induction, followed by consolidation with chemotherapy plus imatinib and, when applicable, by a hematopoietic stem cell transplant. Fifty-one patients (median age 45.9 years) were enrolled in the final sequential protocol. At the end of induction (day +50), 96% of evaluable patients (n=49) achieved a complete hematologic remission; after consolidation, all were in complete hematologic remission. No deaths in induction were recorded. Overall survival and disease-free survival at 60 months are 48.8% and 45.8%, respectively. At day +50 (end of imatinib induction), a more than 1.3 log-reduction of BCR-ABL1 levels was associated with a significantly longer disease-free survival (55.6%, 95%CI: 39.0-79.3 vs. 20%, 95%CI: 5.8-69.1; P=0.03), overall survival (59.1%, 95%CI: 42.3-82.6 vs. 20%, 95%CI: 5.8-69.1; P=0.02) and lower incidence of relapse (20.5%, 95%CI: 7.2-38.6 vs. 60.0%, 95%CI: 21.6-84.3; P=0.01). Mean BCR-ABL1 levels remained significantly higher in patients who subsequently relapsed. Finally, BCR-ABL1

Indexed as

Hematopoietic Stem Cell TransplantationAdolescentAdultAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsCombined Modality TherapyFemaleFusion Proteins, bcr-ablHumansImatinib MesylateMaleMiddle AgedNeoplasm, ResidualPrecursor Cell Lymphoblastic Leukemia-LymphomaProtein Kinase InhibitorsRecurrenceAntineoplastic AgentsFusion Proteins, bcr-ablImatinib MesylateProtein Kinase Inhibitors

Identifiers

PMID27515250
PMCPMC5479612
OpenAlexW2509076190

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.